Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

TELESTA THERAPEUTICS INC T.TST

"Telesta Therapeutics Inc is a biopharmaceutical company. The Company is engaged in the research, development, manufacturing and commercialization of human health products and technologies."


TSX:TST - Post by User

Post by cheetioon Nov 17, 2014 6:38am
321 Views
Post# 23135008

Piece of cake

Piece of cake
nothing to it hey ........... ready a label and re-submit... US okays Sanofi MS drug at last Pharma Times Sunday 16th November, 2014 Sanofi’s Genzyme unit has finally got the thumbs-up from the US Food and Drug Administration for its multiple sclerosis therapy Lemtrada. At the end of last year, the agency issued a complete response letter for Lemtrada (alemtuzumab) saying Genzyme had failed to submit evidence showing that its benefits outweigh its serious adverse effects. The company disagreed vehemently but resubmitted the drug which has now got the thumbs-up 14 months after getting European approval. Because of its safety profile, the FDA noted that use of Lemtrada should generally be reserved for patients who have had an inadequate response to two or more MS drugs. The label includes a boxed warning noting a risk of autoimmune conditions, serious and life-threatening infusion reactions and malignancies including thyroid cancer, melanoma and lymphoproliferative disorders. The approval is based on Phase III trials comparing Lemtrada with Merck KGaA’s Rebif (interferon beta-1a) which showed that it was significantly more effective than the latter at reducing annualised relapse rates. hours. The first treatment course is administered via intravenous infusion on five consecutive days, and thenthree consecutive days 12 months later. Timothy Coetzee, chief advocacy, services and research officer at the National MS Society, said "we are pleased that the voices of the MS community have been recognised and that people with relapsing MS will now have access to a new, need...
<< Previous
Bullboard Posts
Next >>